Stop funding window shoppers. We engineer pre-qualified luxury travel appointments using AI-driven wealth qualification, proprietary data filtering, and our Administrative Dispatcher Methodology. Stop paying inflated per-lead costs. Hire a dedicated team of luxury travel SDRs for a flat $9–$12/hr and only speak to HNW individuals with verified budgets. Backed by a 14-day zero-risk trial.
No high-pressure sales scripts. Your dedicated SDRs use a flat, routine tone to bypass traveler defenses and secure high-show-rate appointments.
We cross-reference high-equity real estate and executive data. Your $9-$12/hr agents only speak to verified luxury travelers with real budgets.
We bypass consumer channels. Your dedicated team secures appointments directly with CEOs and HR Directors for high-value executive offsites.
We never resell data. Your SDRs book exclusive appointments directly onto your calendar, ensuring you never compete over the same prospect.
“Leadsmania transformed our pipeline. The appointments are clean, and knowing we just pay a flat $12/hr for our dedicated team makes our margins highly predictable.”
“Finally, a partner that understands time is money. Switching to dedicated AI-powered SDRs means we've stopped wasting hours on unfunded dreamers.”
“We dropped our cost per booking significantly by using Leadsmania's flat-rate model. Our close rate increased by 35% because we speak directly to decision-makers.”
No. Leadsmania guarantees absolute exclusivity. Every appointment is booked directly onto your agency’s calendar.
We verify intent and financial capacity through concierge profile verification and wealth data proxies before any appointment is set.
By executing strict wealth filtering, we eliminate hours wasted on unfunded itineraries, directing sales payroll toward high-ticket conversions.
We target based on annual revenue minimums and executive titles, confirming budget existence during our audit phase.
Stop wasting time on bad leads. Start closing more deals with dedicated AI-powered SDRs on a 14-day zero-risk trial.